Video

Rapid Readouts: Phase 2 JULIET Trial

Author(s):

Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Related Content
Nausheen Ahmed, MD, MBBS
July 24th 2024

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Michal Taszner, MD
July 17th 2024

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups